Trial ID or NCT#

NCT04417530

Status

recruiting iconRECRUITING

Purpose

The primary objective is to assess safety and efficacy of AU-011 via suprachoroidal injection to treat primary indeterminate lesions and small choroidal melanoma.

Official Title

A Phase 2 Trial of AU-011 Via Suprachoroidal Administration With a Dose Escalation Phase (Open-label, Ascending Single and Repeat Dose) and a Randomized, Masked Dose Expansion Phase Designed to Evaluate the Safety and Efficacy of AU-011 in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Prithvi Mruthyunjaya, MD, MHS
Prithvi Mruthyunjaya, MD, MHS
Ophthalmologist
Professor of Ophthalmology

Contact us to find out if this trial is right for you.

CONTACT

Mariana Nunez
(650) 723-6995